Global Cancer Stem Cell Therapy Market - 2021-2028
発行: DataM Intelligence
ページ情報: 英文 180 Pages
The Global Cancer Stem Cell Therapy Market size was worth US$ YY billion in 2020 and is estimated to reach US$ YY billion by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).
Stem Cell Therapy is a type of regenerative medicine designed to repair damaged cells within the body by reducing inflammation and modulating the immune system. This phenomenon makes stem cell therapy a viable treatment option for a variety of medical conditions. Stem cell transplantation is a type of cancer treatment that helps restore the stem cells responsible for blood-forming in patients who have had their blood-forming stem cells destroyed, either through radiotherapy or chemotherapy. Stem cell cancer treatment is used to help treat patients with certain types of cancers, namely leukemia and lymphoma. However, it can also be used to help treat neuroblastoma as well as multiple myeloma. In a stem cell transplant, the patient receives healthy blood-forming stem cells through a needle in a vein. Once they enter the bloodstream, they will travel to the bone marrow, where they take the place of the cells that were destroyed by treatment. The blood-forming stem cells used in transplants can come from the bone marrow, bloodstream, or umbilical cord. Transplants can be Autologous, Allogeneic, Syngeneic.
Additionally, the adoption of stem cell procedures for managing various types of cancer is increasing demand for stem cell transplants. Source: DataM Intelligence Analysis (2020).
The global Cancer Stem Cell Therapy market growth is driven by the growing incidence of Cancer cases, Increasing demand for therapies, Strong pipeline of drugs and advanced technological facilities are among the key factors driving market growth.
As per the Globocan 2020 fact sheet estimates, about 19,292,789 new cancer cases were diagnosed worldwide. Additionally, according to International Agency for Research on Cancer (IARC) estimates, by 2040, global cancer cases are expected to grow to 27.5 million new cancer cases worldwide. Thus, the demand for stem cell therapy and the increasing incidence of cancer cases are expected to drive the need for advanced cancer therapies to treat patients effectively and grow the market share.
The prevalence of cancer worldwide is driving many vendors in the market to develop novel stem cell therapies. Several drugs are in the late stages of clinical trials and are expected to receive marketing approvals over the forecast period. For instance, Cordgenics, LLC, conducts Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer. The Diagnostic Test: ChemoID Assay
Drug: Standard Chemotherapy is currently in Phase III of clinical trials and is expected to be launched in the US by 2021.
Major side-effects of stem cell transplants are likely to hamper the global Cancer Stem Cell therapy market.
Stem cell transplants cause several immediate side effects such as fatigue, vomiting, low platelets and red blood cells, and diarrhea. It may also cause several long-term effects such as infertility, eye disorders, early menopause, lung and bone damage, and risk of developing other cancer types. Sometimes after allogeneic transplants, Grant Versus Host Disease (GVHD) occurs if the stem cells from the donor aren't a close enough match to the patient's own. These risk factors may hamper the growth of the global cancer stem cell therapy market size.
The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the cancer stem cell therapy market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and esophageal cancers. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the cancer stem cell therapy market. However, the situation is expected to improve gradually.
Based on Product Type, the global Cancer Stem Cell Therapy market is segmented into Autologous Stem Cell Transplants, Allogeneic Stem Cell Transplants and Syngeneic Stem Cell Transplants, Others
An autologous transplant is also called a self- stem cell transplant. This means that a person is their own stem cell donor, and the stem cells that are transferred to replace damaged or destroyed stem cells will have come from their own body. It is also called an autologous bone marrow transplant. Using cells from own body during your stem cell transplant offers some advantages over stem cells from a donor. For example, patients don't need to worry about incompatibility between the donor's cells and their own cells. Advantages of autologous transplant, affordability, the improved survival rate of patients, and increased transplantation procedures are the major factors contributing to the growth of the Autologous segment, as per the official publication of the European Society of Bone and Marrow Transplantation (EBMT). The median total costs for autologous stem cell transplant were $99 899 and for allogeneic transplant were $203 026.
In an allogeneic stem cell transplant, healthy blood stem cells from a donor replace the diseased or damaged bone marrow, and it is also called an allogeneic bone marrow transplant. A donor may include a family member, an acquaintance or someone. These blood stem cells used in the procedure can be collected from the donor's blood, collected from the bone marrow within a donor's hipbone or collected from the blood of a donated umbilical cord.
A syngeneic stem cell transplant is a form of allogeneic transplant, meaning it comes from a donor. The procedure can only receive a syngeneic transplant if the patient has an identical twin or triplet who can donate stem cells. It is used to treat Hodgkin lymphoma, Multiple myeloma, Leukemia, Testicular cancer.
Based on the Application Type, the global Cancer Stem Cell Therapy market is segmented into Hospitals, Clinics, Medical research institutes, Others
Hospitals are the major shareholders of the market. Reason being hospitals provide with maximum health insurance facilities and are a most trusted resource for treatment and also increasing adoption of minimally invasive surgical procedures and also equipped with advanced infrastructure and adequate facilities for the treatment of various cancer types.
North America holds the largest market in the global cancer stem cells market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to stem cell therapy and there are several internationally recognized hospitals and medical institutes, such as Cancer Treatment Centers of America at Midwestern Regional Medical Center, which offer stem cell transplant therapies.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, in collaboration with Fujifilm, Cynata Therapeutics Ltd. has been developing a Pluripotent stem cell (iPSC) -derived treatment for graft-versus-host disease (GvHD), a severe disorder that occurs after bone marrow transplants and critical limb ischemia (CLI).
The Global Cancer Stem Cell Therapy Market is quite competitive with some key competitors like AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems, Thermo Fisher Scientific, Inc, Cellerant Therapeutics, Inc, Celularity Inc, Gamida Cell Ltd, Nohla Therapeutics, Inc, Sumitomo Dainippon Pharma Co. Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, Canadian Cancer Trials Group with NCIC Clinical Trials Group conducted Randomized phase III trial to compare the effectiveness of high dose chemotherapy plus peripheral stem cell transplantation with that of standard therapy in treating women with metastatic or recurrent breast cancer.
Company overview - American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific to form a company with US$ 9 billion in combined revenues.
In March 2020, Thermo Fisher received emergency use authorization from the FDA to test for SARS-CoV-2 to help mitigate the COVID-19 pandemic.
Product Portfolio: The Company's portfolio comprised of include Antibodies, Realtime PCR, cell culture plastics, oligos, primers & probes.
StemPro-34 SFM is a well-referenced tool for driving iPSCs to HSCs.
The global Cancer Stem Cell Therapy report would provide an access to an approx. market data 53 tables, 44 figures and 180 pages.
LIST NOT EXHAUSTIVE